Answers are grounded in this paper and cite their sources.
Demonstrates significantly reduced bleeding rates with subcutaneous emicizumab in hemophilia A without inhibitors, indicating effective prophylaxis over factor VIII.
Emicizumab prophylaxis administered subcutaneously once weekly or every 2 weeks led to a significantly lower bleeding rate than no prophylaxis among persons with hemophilia A without inhibitors; more than half the participants who received prophylaxis had no treated bleeding events. In an intraindividual comparison, emicizumab therapy led to a significantly lower bleeding rate than previous factor VIII prophylaxis. (Funded by F. Hoffmann-La Roche and Chugai Pharmaceutical; HAVEN 3 ClinicalTrials.gov number, NCT02847637 .).
No takes yet. Share an insight, caveat, or question.
Mahlangu et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: